Table 2.
Thirty percent responders at each dose for each dose pathway
| Dose pathway | 150 mg/day
|
300 mg/day
|
450 mg/day
|
600 mg/day
|
||||
|---|---|---|---|---|---|---|---|---|
| Na | n (%)b | Na | n (%)b | Na | n (%)b | Na | n (%)b | |
| 150 mg/day | ||||||||
| Responder | 67 | 35 (52.2) | – | – | – | |||
| Non-responder | 32 (47.8) | |||||||
| 150 to 300 mg/day | ||||||||
| Responder | 146 | 46 (31.5) | 100 | 43 (43.0) | – | – | ||
| Non-responder | 100 (68.5) | 57 (57.0) | ||||||
| 150 to 300 to 450 mg/day | ||||||||
| Responder | 144 | 22 (15.3) | 122 | 36 (29.5) | 86 | 31 (36.1) | – | |
| Non-responder | 122 (84.7) | 86 (70.5) | 55 (63.9) | |||||
| 150 to 300 to 450 to 600 mg/day | ||||||||
| Responder | 298 | 26 (8.7) | 272 | 41 (15.1) | 231 | 43 (18.6) | 188 | 28 (14.9) |
| Non-responder | 272 (91.3) | 231 (84.9) | 188 (81.4) | 160 (85.1) | ||||
| 150 to 300 to 600 mg/day | ||||||||
| Responder | 46 | 7 (15.2) | 39 | 3 (7.7) | – | 36 | 6 (16.7) | |
| Non-responder | 39 (84.8) | 36 (92.3) | 30 (83.3) | |||||
| 300 to 600 mg/day | ||||||||
| Responder | – | 16 | 8 (50.0) | – | 8 | 2 (25.0) | ||
| Non-responder | 8 (50.0) | 6 (75.0) | ||||||
Notes:
a
Number of subjects available for the dose level (i.e., were non-responders at the previous dose in the dose pathway).
b
Number (percentage) of patients who were 30% responders at that dose.